Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HOMO 16 is a multi-ingredient therapeutic formulation developed by Sinsan Pharmaceuticals, primarily indicated for the management of metabolic and cardiovascular health in patients with diabetes. The core formulation is a combination of B-vitamins (Pyridoxine, Cyanocobalamin, and Folic Acid) and essential minerals (Zinc, Selenium, and Chromium). Its primary mechanism of action involves the reduction of homocysteine levels—a significant risk factor for cardiovascular disease—by providing the necessary cofactors for the methionine and cystathionine metabolic pathways. Additionally, Chromium picolinate is included to enhance insulin sensitivity and glucose metabolism, while Zinc and Selenium provide antioxidant support to mitigate oxidative stress associated with chronic metabolic conditions. The product is available in specialized variants: HOMO 16 D, which incorporates Vitamin D3 for bone and immune health, and HOMO 16 LC, which contains L-carnitine to support cellular energy production and fatty acid metabolism. It is approved and marketed for indications such as diabetic neuropathy and cardiovascular risk reduction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HOMO 16.